1. Use of selenium–silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men
- Author
-
Vladimír Študent, Vilím Šimánek, Jitka Ulrichová, Ales Vidlar, Jana Vrbkova, and Jitka Vostálová
- Subjects
Male ,medicine.medical_specialty ,Prostatic Hyperplasia ,Urology ,Urination ,Pharmaceutical Science ,chemistry.chemical_element ,Placebo ,Selenium ,Double-Blind Method ,Lower Urinary Tract Symptoms ,Lower urinary tract symptoms ,Drug Discovery ,medicine ,Humans ,Milk Thistle ,Testosterone ,Adverse effect ,Aged ,Pharmacology ,Gynecology ,Plant Extracts ,business.industry ,Middle Aged ,Prostate-Specific Antigen ,Hyperplasia ,medicine.disease ,Trace Elements ,Drug Combinations ,Prostate-specific antigen ,Complementary and alternative medicine ,chemistry ,Molecular Medicine ,International Prostate Symptom Score ,business ,Phytotherapy ,Silymarin - Abstract
The aim of this double-blind, placebo controlled clinical trial was to assess the effects of a combination of selenium and silymarin in men with lower urinary tract symptoms, benign prostatic hyperplasia and a prostate specific antigen (PSA) ≤2.5ng/ml. The volunteers were randomized to two groups: the first one (n=26) received 240μg selenium (in the form of yeast l-selenomethionine) plus 570mg silymarin daily for 6 months and the second (n=29) received placebo. Outcome measures were changes in the International Prostate Symptom Score (IPSS), bladder volume (V), urinary flow rate, ultrasound estimated postvoid residual urine volume (RV), serum PSA, testosterone and selenium levels, safety clinical biochemistry, hematology and oxidative stress parameters at baseline and on day 180. The results showed statistically significant differences (p
- Published
- 2013
- Full Text
- View/download PDF